Treatment of patients with metastatic urothelial cancer "Unfit" for cisplatin-based chemotherapy

Journal of Clinical Oncology

Volumn 29, Issue 17, 2011, Pages 2432-2438

  Galsky, Matthew D ^a   Hahn, Noah M ^c   Rosenberg, Jonathan ^d   Sonpavde, Guru ^e   Hutson, Thomas ^f   Oh, William K ^a   Dreicer, Robert ^g   Vogelzang, Nicholas ^h   Sternberg, Cora N ⁱ   Bajorin, Dean F ^b   Bellmunt, Joaquim ^j  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c INDIANA UNIVERSITY   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h Department of Hematology Oncology   (United States)

ⁱ SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^j HOSPITAL DEL MAR   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CREATININE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; METHOTREXATE; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; SUNITINIB; VINBLASTINE; VINFLUNINE;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COMORBIDITY; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEBRILE NEUTROPENIA; GLOMERULUS FILTRATION RATE; HEARING LOSS; HEART EJECTION FRACTION; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY PELVIS; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); METASTASIS; METASTATIC UROTHELIAL CARCINOMA; MORBIDITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROPATHY; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SIDE EFFECT; SOLITARY KIDNEY; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMORBIDITY; HUMANS; KIDNEY; NEOPLASM METASTASIS; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 79959191493     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.34.8433     Document Type: Review

References (59)

1. Ferlay J, Shin HR, Bray F, et al: GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer, 2010. http://globocan.iarc.fr
2. Bamias A, Aravantinos G, Deliveliotis C, et al: Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 22:220-228, 2004 (Pubitemid 41095085)
3. Dreicer R, Manola J, Roth BJ, et al: Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100:1639-1645, 2004 (Pubitemid 38456340)
4. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 10:1066-1073, 1992
5. Sternberg CN, de Mulder PH, Schornagel JH, et al: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19:2638-2646, 2001 (Pubitemid 32441368)
6. von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077, 2000
7. Altekruse SF, Kosary CL, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, based on November 2009 SEER data submission, posted to the SEER web site, 2010. http://seer.cancer.gov/csr/1975-2007/
8. Dash A, Galsky MD, Vickers AJ, et al: Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107:506-513, 2006 (Pubitemid 44107210)
9. Bellmunt J, Albanell J, Gallego OS, et al: Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 70:1974-1979, 1992
10. Bellmunt J, de Wit R, Albanell J, et al: A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer 37:2212-2215, 2001
11. Bellmunt J, Maroto P, Mellado B, et al: Phase II study of sunitinib as first line treatment in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy. 2008 Genitourinary Cancers Symposium (abstr 291)
12. De Santis M, Bellmunt J, Mead G, et al: Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: Phase II - Results of EORTC study 30986. J Clin Oncol 27:5634-5639, 2009
13. Galsky MD, Iasonos A, Mironov S, et al: Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer 109:549-555, 2007 (Pubitemid 46190963)
14. Linardou H, Aravantinos G, Efstathiou E, et al: Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology 64:479-484, 2004 (Pubitemid 39200741)
15. Bellmunt J, Ribas A, Eres N, et al: Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80:1966-1972, 1997
16. Dogliotti L, Carteni G, Siena S, et al: Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: Results of a randomized phase 2 trial. Eur Urol 52:134-141, 2007 (Pubitemid 46803003)
17. Petrioli R, Frediani B, Manganelli A, et al: Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study. Cancer 77:344-351, 1996
18. Galsky MD, Chen GJ, Oh WK, et al: Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol (in press)
19. de Wit R, European Organization for Research and Treatment: Overview of bladder cancer trials in the European Organization for Research and Treatment. Cancer 97:2120-2126, 2003
20. Bamias A, Lainakis G, Kastritis E, et al: Biweekly carboplatin/ gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: Report of efficacy, quality of life and geriatric assessment. Oncology 73:290-297, 2007 (Pubitemid 351862018)
21. Carles J, Esteban E, Climent M, et al: Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann Oncol 18:1359-1362, 2007 (Pubitemid 47305010)
22. Small EJ, Fippin LJ, Ernest ML, et al: A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer 78:1775-1780, 1996 (Pubitemid 26330906)
23. Vaughn DJ, Manola J, Dreicer R, et al: Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): A trial of the Eastern Cooperative Oncology Group. Cancer 95:1022-1027, 2002 (Pubitemid 34925352)
24. Lichtman SM, Buchholtz M, Marino J, et al: Use of cisplatin for elderly patients. Age Ageing 21:202-204, 1992
25. Raghavan D, Grundy R, Greenaway TM, et al: Pre-emptive (neo-adjuvant) chemotherapy prior to radical radiotherapy for fit septuagenarians with bladder cancer: Age itself is not a contra-indication. Br J Urol 62:154-159, 1988
26. Belani CP, Fossella F: Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 104:2766-2774, 2005 (Pubitemid 41798287)
27. Langer CJ, Manola J, Bernardo P, et al: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:173-181, 2002 (Pubitemid 34162751)
28. Schild SE, Stella PJ, Geyer SM, et al: The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 21:3201-3206, 2003 (Pubitemid 46606250)
29. Bajorin DF, Dodd PM, Mazumdar M, et al: Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173-3181, 1999 (Pubitemid 29470648)
30. Bajorin DF, Ostrovnaya I, Iasonos A, et al: A nomogram predicting survival of patients (pts) with metastatic or unresectable urothelial cancer (UC) treated with cisplatin-based chemotherapy. J Clin Oncol 25:248s, 2007 (suppl; abstr 5055)
31. Bellmunt J, Choueiri TK, Fougeray R, et al: Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28:1850-1855, 2010
32. Hurria A, Cirrincione CT, Muss HB, et al: Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401. J Clin Oncol 29:1290-1296, 2011
33. Castagneto B, Zai S, Marenco D, et al: Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: Response to treatment and correlation with the comprehensive geriatric assessment. Oncology 67:27-32, 2004 (Pubitemid 39370347)
34. Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982 (Pubitemid 12049914)
35. Launay-Vacher V, Chatelut E, Lichtman SM, et al: Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 18:1314-1321, 2007 (Pubitemid 47305003)
36. Levey AS, Stevens LA, Schmid CH, et al: A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604-612, 2009
37. Cho KS, Joung JY, Seo HK, et al: Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract. Cancer Chemother Pharmacol 67:769-774. 2011
38. von der Maase H, Andersen L, Crinò L, et al: Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial. Ann Oncol 10:1461-1465, 1999 (Pubitemid 30017056)
39. Saxman SB, Propert KJ, Einhorn LH, et al: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 15:2564-2569, 1997 (Pubitemid 27289886)
40. Lee L, Cheung WY, Atkinson E, et al: Impact of comorbidity on chemotherapy use and outcomes in solid tumors: A systematic review. J Clin Oncol 29:106-117, 2011
41. Asmis TR, Ding K, Seymour L, et al: Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: A review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 26:54-59, 2008
42. Breen D, Barlési F, Zemerli M, et al: Results and impact of routine assessment of comorbidity in elderly patients with non-small-cell lung cancer aged > 80 years. Clin Lung Cancer 8:331-334, 2007 (Pubitemid 46714705)
43. Gronberg BH, Sundstrom S, Kaasa S, et al: Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer 46:2225-2234, 2010
44. Juan O, Albert A, Campos JM, et al: Measurement and impact of co-morbidity in elderly patients with advanced non-small cell lung cancer treated with chemotherapy: A phase II study of weekly paclitaxel. Acta Oncol 46:367-373, 2007 (Pubitemid 46625042)
45. Li J, Chen P, Dai CH, et al: Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. Oncology 76:355-362, 2009
46. Moscetti L, Nelli F, Padalino D, et al: Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: Impact of comorbidities on safety and efficacy outcome. J Chemother 17:685-692, 2005 (Pubitemid 43097759)
47. Nakai Y, Isayama H, Sasaki T, et al: Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. Crit Rev Oncol Hematol [epub ahead of print on June 23, 2010]
48. LeCaer H, Barlesi F, Robinet G, et al: An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study. Lung Cancer 57:72-78, 2007 (Pubitemid 46850769)
49. Mir O, Alexandre J, Ropert S, et al: Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: A single-center experience. Anticancer Drugs 20:105-108, 2009
50. Rybak LP, Ramkumar V: Ototoxicity. Kidney Int 72:931-935, 2007 (Pubitemid 47530566)
51. Rademaker-Lakhai JM, Crul M, Zuur L, et al: Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol 24:918-924, 2006 (Pubitemid 46638845)
52. National Cancer Institute, Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events (CTCAE) version 4. http://evs.nci.nih. gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf
53. Park SB, Krishnan AV, Lin CS, et al: Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15:3081-3094, 2008
54. Galsky MD, Hahn NM, Rosenberg J, et al: A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 12:211-214, 2011
55. Ricci S, Galli L, Chioni A, et al: Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens. Cancer 95:1444-1450, 2002
56. Türkölmez K, Bedük Y, Baltaci S, et al: Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy. Eur Urol 44:682-686, 2003 (Pubitemid 37542926)
57. De Santis M, Bellmunt J, Mead G, et al: Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy (CHT): Phase III results of EORTC study 30986. J Clin Oncol 28:346s, 2010 (suppl; abstr LBA4519)
58. Hussain SA, Stocken DD, Riley P, et al: A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer 91:844-849, 2004 (Pubitemid 39273773)
59. Calabrò F, Lorusso V, Rosati G, et al: Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer 115:2652-2659, 2009